NCT05029869

Monitoring Minimal Residual Disease in Gastric Cancer by Liquid Biopsy Study Description

Monitoring Minimal Residual Disease in Gastric Cancer by Liquid Biopsy

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 100 (estimated)
• Sponsor: University Medical Center Ho Chi Minh City (UMC) · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the use of Next Generation Sequencing (NGS) to detect circulating tumor DNA in gastric cancer patients after gastrectomy

Detailed description

Gastric cancer is the fourth most common cancer in Vietnam with high mortality rate. Patients at early stages undergo radical gastrectomy with curative intent, but the remaining tumor cells, termed as minimal residual disease (MRD), can later cause relapse. Conventional methods to monitor MRD such as imaging and blood tests for biomarkers such as CEA are not sensitive and specific enough. ctDNA has recently emerged as a promising noninvasive marker with high accuracy to monitor MRD and detect relapse in many cancers such as breast and colorectal cancers. However, its application in gastric cancer has not been extensively evaluated. Therefore, this study aims to use advanced NGS technologies to detect ctDNA in liquid biopsy as a biomarker to monitor MRD after radical gastrectomy.

Conditions

• Gastric Cancer
• ctDNA

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	ctDNA	The blood samples for ctDNA and other tumor markers will be first collected within 14 days before surgery, and then be tested after gastrectomy in scheduled interval

Timeline

• Start date: 2021-10-04
• Primary completion: 2026-12-30
• Completion: 2026-12-30
• First posted: 2021-09-01
• Last updated: 2025-08-13

Locations

1 site across 1 country: Vietnam